

Drug Discovery for Neglected Diseases

Guest Editors:

Dr. Valeria Patricia Sülzen

Cátedra de Farmacognosia,
Departamento de Farmacología,
Facultad de Farmacia y
Bioquímica, Universidad de
Buenos Aires
Instituto de Química y
Metabolismo del Fármaco
(IQIMEFA) (UBA- CONICET),
Junín 956, 1113 Buenos Aires,
República Argentina
vsulsen@ffyb.uba.ar

Dr. Albertina Moglioni

Cátedra de Química Medicinal,
Departamento de Farmacología,
Facultad de Farmacia y
Bioquímica, Universidad de
Buenos Aires.
Instituto de Química y
Metabolismo del Fármaco
(IQIMEFA) (UBA- CONICET),
Junín 956, 1113 Buenos Aires,
República Argentina.
amoglio@ffyb.uba.ar

Deadline for manuscript
submissions:

30 April 2019




mdpi.com/si/15062

Message from the Guest Editors

The Drug Discovery for Neglected Diseases International Congress 2018 (DDNDIC 2018) will be framed in celebration of the 35th anniversary of the creation of the Institute for Drug Chemistry and Metabolism (IQIMEFA), University of Buenos Aires—National Scientific and Technical Research Council. The 4th Scientific Meeting of the Research Network Natural Products against Neglected Diseases (ResNet NPND) will be carried out together with the DDNDIC 2018. Both events will be held simultaneously at the Faculty of Pharmacy and Biochemistry, University of Buenos Aires, Buenos Aires, Argentina.

The Special Issue is to publish the results presented at the congress, as well as the recent advances made in the field of neglected diseases. It will be focused on the discovery and development of natural and synthetic drugs for neglected diseases and other diseases having consequences in public health and of high relevance worldwide. Research works dealing with this group of diseases in the areas of natural compounds, drug design, drug synthesis, in vitro and in vivo assays, mechanisms of action, epidemiology and individual and environmental prophylaxis will be considered for publication.



an Open Access Journal by MDPI

Editor-in-Chief

Dr. Derek J. McPhee

Senior Director, Technology
Strategy, Amyris, Inc., 5885 Hollis
St, Suite 100, Emeryville, CA
94608, USA

Message from the Editor-in-Chief

As the premier open access journal dedicated to experimental organic chemistry, and now in its 22nd year of publication, the papers published in *Molecules* span from classical synthetic methodology to natural product isolation and characterization, as well as physicochemical studies and the applications of these molecules as pharmaceuticals, catalysts and novel materials. Pushing the boundaries of the discipline, we invite papers on multidisciplinary topics bridging biochemistry, biophysics and materials science, as well as timely reviews and topical issues on cutting edge fields in all these areas.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High visibility: indexed by the Science Citation Index Expanded (Web of Science), MEDLINE (PubMed), Scopus and other databases.

Rapid publication: manuscripts are peer-reviewed and a first decision provided to authors approximately 12.6 days after submission; acceptance to publication is undertaken in 4.4 days (median values for papers published in this journal in the second half of 2018).

Contact Us

Molecules
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
Fax: +41 61 302 89 18
www.mdpi.com

mdpi.com/journal/molecules
molecules@mdpi.com
@Molecules_MDPI